Threat of counterfeit drug imports
As the U.S. Senate takes up legislation to ease restrictions on prescription-drug importation by U.S. consumers, Professor Bryan A. Liang, warns of potential health risks due to the expansion of the prescription-drug "grey market" that may result. Professor Liang, executive director of the Institute of Health Law Studies at California Western School of Law in San Diego is a patient rights advocate and an expert on the issue of prescription drug importation.